Recent and anticipated novel drug approvals (3Q 2025 through 2Q 2026)
American Journal of Health-System Pharmacy · 2025
DOI: 10.1093/ajhp/zxaf237 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Matthew H Rim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Drug Approval, Pharmacists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Purpose
Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals. Summary Selected drug approvals anticipated in the 12-month period covering the third quarter of 2025 through the second quarter of 2026 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 56 novel drugs awaiting US Food and Drug Administration approval. This year’s pipeline features novel therapies for rare and ultrarare diseases, targeted cancer treatments, and new agents for various disease states expected to impact hospitals and outpatient clinical settings.
Conclusion
Novel therapies continue to strengthen the current drug pipeline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Northwestern Medicine, Chicago, IL, USA.
- IPD Analytics, Aventura, FL, USA.
Zitieren
APA
Rim, M. H., Joseph, R., Endriukaitis, L., Tran, T., & Levitsky, A. M. (2025). Recent and anticipated novel drug approvals (3Q 2025 through 2Q 2026). American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf237
Vancouver
Rim MH, Joseph R, Endriukaitis L, Tran T, Levitsky AM. Recent and anticipated novel drug approvals (3Q 2025 through 2Q 2026). American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf237
BibTeX
@article{Rim2025,
author = {Rim, Matthew H and Joseph, Rachel and Endriukaitis, Lauren and Tran, Thuy and Levitsky, Andrew M},
title = {Recent and anticipated novel drug approvals (3Q 2025 through 2Q 2026)},
journal = {American Journal of Health-System Pharmacy},
year = {2025},
doi = {10.1093/ajhp/zxaf237}
}
EUVIMED